Haemonetics (NYSE: HAE) reported Q2 EPS of $0.44, $0.05 better than the analyst estimate of $0.39. Revenue for the quarter came in at $219.7 million versus the consensus estimate of $226.5 million.

For earnings history and earnings-related data on Haemonetics (HAE) click here.